Abstract LB425: Search for targets of anti-cancer immunity in patients receiving an off-the-shelf cancer’s dark matter vaccine, DPV-001, combined with anti-PD-1 +/- anti-GITR in head and neck squamous cell cancer (HNSCC)

Traci Hilton(UbiVac (United States)), Bernard A. Fox(Oregon Health & Science University), Christopher Paustian(UbiVac (United States)), Noriko Iwamoto(Shimadzu (Japan)), Marcus Couey(Providence Portland Medical Center), K Ueda(Japanese Foundation For Cancer Research), Yuriko Minegishi(National Institutes of Health), Tarsem Moudgil(Providence Portland Medical Center), Lessli Rushforth(Providence Portland Medical Center), Shawn M. Jensen(Providence Portland Medical Center), Venkatesh Rajamanickam(Cancer Institute (WIA)), Carlo Bifulco(Providence Health & Services), Olivier Fesneau(Université Claude Bernard Lyon 1), Noah D. Simons(Providence Portland Medical Center), Yoshinobu Koguchi(Providence Portland Medical Center), Brian Piening(Providence College), Patrick Rethwisch(Providence Portland Medical Center), Ryan Meng(Providence Portland Medical Center), Richard B. Bell, Elie Adwani, Brady Bernard(Providence Portland Medical Center), Irene Shih, Walter J. Urba, Guo Hui Gan, Jianguo Huang, Takashi Shimada(Shimadzu (Japan)), Thomas M. Duhen, Eric Tran, Christie Tanisha, Matthew E. Taylor, Rom Leidner, Sierra J. Smith, Annie Long, Abigail Staeck, William L. Redmod, Myungkyu Jang, Tijana Jovanovic, Hong‐Ming Hu(Viva Biotech (China))
Cancer Research
April 17, 2026
Cited by 0


Related Papers